Developer docs
API playgroundTry for free, no card

Search company profiles

Lotus Clinical Research

Full company profile

uuid000cc4c

Namestring
Lotus Clinical Research
Legal namestring
Lotus Clinical Research, LLC
Websiteurl
lotuscr.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Lotus Clinical Research is a US-based, privately held contract research organization (CRO) founded in 2014 and headquartered in Edison, New Jersey, specializing in clinical development for neuroscience (psychiatry, pain, neurology, neuropsychiatry, addiction) and metabolic (obesity, diabetes, MASH) indications. The company delivers full-service Phase I–IV trial capabilities — project management, clinical monitoring, medical monitoring, EDC/data management, biostatistics, PK/PD modeling, and quality operations — augmented by a portfolio of proprietary scientific solutions: Global Rater Training & Certification (30+ years, 30+ countries), the Placebo Response Mitigation (PRM) program (deployed in 50+ studies), the Unified Site Methodology (USM) program, and centralized Eligibility Review. Summit Analytical, a wholly-owned division, provides specialized biostatistics, statistical programming, and PK/PD modeling, while the NeuroKit CNS testing platform (exclusive US partnership with CHDR, launched October 2025) extends Lotus's early-phase pharmacodynamic assessment capabilities.

The company's defining structural advantage is common ownership with Evolution Research Group (ERG), which gives it priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units in Miami (CPMI) and Columbus (OCT). This integrated CRO-site model shortens contracting, legal, and startup timelines and is positioned as the company's primary differentiator versus standalone CROs. The technology stack combines Veeva Vault Clinical Suite (EDC, CTMS, eTMF), ETQ Reliance QMS, Trialogics clinical trial software, and validated Phoenix WinNonlin for PK analysis; databases are 21 CFR Part 11 and CDISC-compliant and aligned with ICH-E6(R3) GCP standards.

Lotus operates a B2B enterprise sales model, engaging pharmaceutical and biotechnology sponsors through an RFP/bid process with scientific leadership review at the bid stage and dedicated business development through study execution. Revenue is generated through custom-quoted professional-services contracts — no public pricing tiers are disclosed. Customer logos (Pacira BioSciences, Xgene Pharmaceutical, South Rampart Pharma, Small Pharma, Concentric) are concentrated in pain and CNS programs for mid-cap and small-cap sponsors. The company claims contributions to 32 FDA approvals since 2023 (27% of all US drug approvals) and more than 3,400 studies cumulatively with ERG, positioning itself as a high-throughput specialty CRO. Leadership is led by President Dr. William Martin (former Alkermes, Pfizer) and COO Lisa Cox, with no disclosed institutional investors; the firm is founder/management-owned under an LLC structure.

Short descriptiontext

Lotus Clinical Research is a US-based specialty CRO providing full-service Phase I–IV clinical trial services for pharmaceutical and biotechnology sponsors, with deep expertise in CNS, pain, neurology, addiction, and metabolic indications, supported by an integrated site network via Evolution Research Group and proprietary scientific solutions including rater training, placebo response mitigation, and the NeuroKit CNS testing platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew Providence, United States
HQ citystring
New Providence
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research organization, contract research services, neuroscience clinical trials, metabolic clinical research, Phase I clinical pharmacology
Industry1 code
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Full-Service CRO Services
TypeProfessional Services
Description

Comprehensive clinical research organization services including project management, clinical monitoring, medical monitoring, EDC & data management, biostatistics, PK/PD modeling, and quality operations. Revenue generated through professional services contracts with pharmaceutical and biotechnology sponsors.

lotuscr.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Summit Analytical
Description

A wholly-owned division of Lotus Clinical Research providing biostatistical support across the full development lifecycle from early-phase trials to post-marketing and real-world evidence studies.

lotuscr.com
Core offering1 text field

Lotus Clinical Research is a full-service global Contract Research Organization (CRO) that runs neuroscience and metabolic clinical trials from first-in-human through late-phase development. The firm delivers project management, clinical monitoring, medical monitoring, EDC and data management, biostatistics, PK/PD modeling, and quality operations, complemented by proprietary scientific solutions such as Placebo Response Mitigation, Global Rater Training, and Unified Site Methodology. Through common ownership with Evolution Research Group (ERG), Lotus has priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lotus Clinical Research operates as a global CRO (Contract Research Organization) offering a comprehensive, integrated suite of clinical trial services. The company is structured around core CRO services (Project Management, Clinical Monitoring, Medical Monitoring, EDC & Data Management, Biostatistics, PK/PD Modeling, and Quality Operations) complemented by specialized Scientific Solutions (Global Rater Training & Certification, Placebo Response Mitigation, Unified Site Methodology, Eligibility Review, Medical Writing, and Scientific Consultation). A key differentiator is the company's common ownership with Evolution Research Group (ERG), providing integrated access to a network of 20+ wholly-owned US research sites, 400+ beds, and dedicated Phase I units. The Summit Analytical division delivers specialized biostatistics and statistical programming, while the NeuroKit CNS testing platform (developed in partnership with CHDR) provides portable pharmacodynamic assessments. Services span Phase I through Phase IV trials across neuroscience (psychiatry, pain, neurology, addiction) and metabolic (obesity, diabetes, MASH) therapeutic areas, supported by a Scientific Leadership Team of 47 MDs and 12 PhDs/PsyDs.

Product and service19 records
1Project Management
CategoryCore CRO Service
Description

Clinical trial project management services providing operational leadership, timeline management, risk mitigation, vendor coordination, and team communication. Project managers have average 10+ years industry tenure and act as extensions of sponsor teams.

2Clinical Monitoring
3Medical Monitoring
4EDC & Data Management
5Biostatistics & Summit Analytical
6PK/PD Modeling & Simulation
7Quality Operations
8Global Rater Training & Certification
9Placebo Response Mitigation (PRM)
10Unified Site Methodology (USM) Program
11Eligibility Review
12Medical Writing
13Clinical Development & Scientific Consultation
14NeuroKit CNS Testing Platform
CategoryTechnology Platform
Description

Portable CNS testing platform adapted from CHDR's NeuroCart system, providing high-quality standardized CNS assessments including adaptive tracking, body sway, N-back test, VAS scales, saccadic eye movement, and smooth pursuit eye movement for Phase I-IIa trials. Available exclusively in the US through Lotus and ERG.

15Phase I Clinical Pharmacology Units
16Renal & Hepatic Studies
17Biomarkers
18Cardiac Safety
19ERG Site Network
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-13
Description

Exclusive US partnership to bring NeuroKit CNS testing platform to the US market. NeuroKit is adapted from CHDR's NeuroCart system and is available exclusively in the US through Lotus and ERG. Clinical Pharmacology of Miami (CPMI) is the first US site to deploy the platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-30
Description

Expanded partnership using Veeva Vault Clinical Suite including Vault EDC, Vault CTMS, and Vault eTMF. The partnership enables substantial decrease in clinical trial startup time and improved operational efficiency across Lotus studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Common ownership partnership providing integrated CRO and site network services. ERG operates 20 wholly-owned US-based research sites with 400+ beds, nine surgical centers, and Phase I units. Lotus-Sponsor studies are prioritized within the ERG network. The collaboration enables rapid study startup and prioritized enrollment for Lotus clients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ERG holds membership in the FNIH Biomarkers Consortium with representation on the Metabolic Diseases Steering Committee. Subject matter experts contribute to supporting crucial development programs in metabolic diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest global full-service CRO and clinical technology vendor with deep CNS and metabolic capabilities. Lotus competes for the same enterprise pharma accounts on bundled full-service offerings, though IQVIA's breadth dwarfs Lotus' specialty focus.

TypeDirect peer
Description

Mid-sized specialty CRO with deep CNS, pain, and cardiometabolic expertise. Closest direct competitor to Lotus—competes for the same pharma/biotech sponsors running CNS and metabolic trials with comparable therapeutic-area focus and similar size/scale.

TypeDirect peer
Description

Specialty CRO emphasizing CNS, oncology, and rare disease trials with similar full-service model (project management through biostatistics). Lotus competes head-to-head on CNS and metabolic RFPs; now owned by KCR/Croone.

TypeBroad incumbent
Description

Top global full-service CRO spun out from LabCorp in 2023 with end-to-end Phase I-IV capabilities including CNS and metabolic therapeutic areas. Competes directly for mid- to large-pharma full-service outsourcing mandates.

TypeBroad incumbent
Description

Top-5 global CRO with broad CNS and metabolic therapeutic expertise acquired through legacy and recent clinical operations build-out. Competes for the same large-pharma outsourced trial mandates.

TypeBroad incumbent
Description

Largest pure-play global CRO (post-PRA merger) with full therapeutic-area coverage including CNS and metabolic. Competes with Lotus for large-pharma full-service Phase II-IV trials and biotech sponsor mandates.

TypeBroad incumbent
Description

Global biopharmaceutical services organization spanning clinical development and commercial—offers comparable full-service CNS/metabolic CRO capabilities at larger scale. Competes on enterprise pharma outsourcing relationships and global trial footprint.

TypeDirect peer
Description

Major clinical trial technology and eCOA/ePRO vendor serving CNS and metabolic trials. Comparable function to Lotus' Veeva-integrated EDC/CTMS/eTMF stack and NeuroKit platform—competes on clinical trial informatics and endpoint data quality.

TypeDirect peer
Description

Early-phase CRO with dedicated Phase I clinical pharmacology units and integrated preclinical-to-clinical services. Direct overlap with Lotus' Clinical Pharmacology of Miami and Ohio Clinical Trials Phase I units serving healthy volunteer and special population studies.

TypeEmerging player
Description

Niche pain-CRO consultancy specializing in analgesic trial design, endpoint selection, and pain measurement—overlapping with Lotus' analgesic/pain trial focus (~600+ pain studies) and competing for the same sponsor pain franchise programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lotus Clinical Research

Contract Research Organization (CRO) Serviceslotuscr.com

Lotus Clinical Research is a US-based specialty CRO providing full-service Phase I–IV clinical trial services for pharmaceutical and biotechnology sponsors, with deep expertise in CNS, pain, neurology, addiction, and metabolic indications, supported by an integrated site network via Evolution Research Group and proprietary scientific solutions including rater training, placebo response mitigation, and the NeuroKit CNS testing platform.

What Lotus Clinical Research does

Lotus Clinical Research is a US-based, privately held contract research organization (CRO) founded in 2014 and headquartered in Edison, New Jersey, specializing in clinical development for neuroscience (psychiatry, pain, neurology, neuropsychiatry, addiction) and metabolic (obesity, diabetes, MASH) indications. The company delivers full-service Phase I–IV trial capabilities — project management, clinical monitoring, medical monitoring, EDC/data management, biostatistics, PK/PD modeling, and quality operations — augmented by a portfolio of proprietary scientific solutions: Global Rater Training & Certification (30+ years, 30+ countries), the Placebo Response Mitigation (PRM) program (deployed in 50+ studies), the Unified Site Methodology (USM) program, and centralized Eligibility Review. Summit Analytical, a wholly-owned division, provides specialized biostatistics, statistical programming, and PK/PD modeling, while the NeuroKit CNS testing platform (exclusive US partnership with CHDR, launched October 2025) extends Lotus's early-phase pharmacodynamic assessment capabilities.

The company's defining structural advantage is common ownership with Evolution Research Group (ERG), which gives it priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units in Miami (CPMI) and Columbus (OCT). This integrated CRO-site model shortens contracting, legal, and startup timelines and is positioned as the company's primary differentiator versus standalone CROs. The technology stack combines Veeva Vault Clinical Suite (EDC, CTMS, eTMF), ETQ Reliance QMS, Trialogics clinical trial software, and validated Phoenix WinNonlin for PK analysis; databases are 21 CFR Part 11 and CDISC-compliant and aligned with ICH-E6(R3) GCP standards.

Lotus operates a B2B enterprise sales model, engaging pharmaceutical and biotechnology sponsors through an RFP/bid process with scientific leadership review at the bid stage and dedicated business development through study execution. Revenue is generated through custom-quoted professional-services contracts — no public pricing tiers are disclosed. Customer logos (Pacira BioSciences, Xgene Pharmaceutical, South Rampart Pharma, Small Pharma, Concentric) are concentrated in pain and CNS programs for mid-cap and small-cap sponsors. The company claims contributions to 32 FDA approvals since 2023 (27% of all US drug approvals) and more than 3,400 studies cumulatively with ERG, positioning itself as a high-throughput specialty CRO. Leadership is led by President Dr. William Martin (former Alkermes, Pfizer) and COO Lisa Cox, with no disclosed institutional investors; the firm is founder/management-owned under an LLC structure.

Lotus Clinical Research firmographics

Firmographics
Name
Lotus Clinical Research
Legal name
Lotus Clinical Research, LLC
Website
https://lotuscr.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Lotus Clinical Research is a US-based specialty CRO providing full-service Phase I–IV clinical trial services for pharmaceutical and biotechnology sponsors, with deep expertise in CNS, pain, neurology, addiction, and metabolic indications, supported by an integrated site network via Evolution Research Group and proprietary scientific solutions including rater training, placebo response mitigation, and the NeuroKit CNS testing platform.
Ownership category
akta.pro rank

Lotus Clinical Research industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Clinical research organization
  • Contract research services
  • Neuroscience clinical trials
  • Metabolic clinical research
  • Phase I clinical pharmacology

Where Lotus Clinical Research is headquartered

Location

Headquarters

HQ city
New Providence
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Lotus Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Full-Service CRO Services: Comprehensive clinical research organization services including project management, clinical monitoring, medical monitoring, EDC & data management, biostatistics, PK/PD modeling, and quality operations. Revenue generated through professional services contracts with pharmaceutical and biotechnology sponsors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Lotus Clinical Research product offering

Product offering

Core offering

Lotus Clinical Research is a full-service global Contract Research Organization (CRO) that runs neuroscience and metabolic clinical trials from first-in-human through late-phase development. The firm delivers project management, clinical monitoring, medical monitoring, EDC and data management, biostatistics, PK/PD modeling, and quality operations, complemented by proprietary scientific solutions such as Placebo Response Mitigation, Global Rater Training, and Unified Site Methodology. Through common ownership with Evolution Research Group (ERG), Lotus has priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units.

Product overview

Lotus Clinical Research operates as a global CRO (Contract Research Organization) offering a comprehensive, integrated suite of clinical trial services. The company is structured around core CRO services (Project Management, Clinical Monitoring, Medical Monitoring, EDC & Data Management, Biostatistics, PK/PD Modeling, and Quality Operations) complemented by specialized Scientific Solutions (Global Rater Training & Certification, Placebo Response Mitigation, Unified Site Methodology, Eligibility Review, Medical Writing, and Scientific Consultation). A key differentiator is the company's common ownership with Evolution Research Group (ERG), providing integrated access to a network of 20+ wholly-owned US research sites, 400+ beds, and dedicated Phase I units. The Summit Analytical division delivers specialized biostatistics and statistical programming, while the NeuroKit CNS testing platform (developed in partnership with CHDR) provides portable pharmacodynamic assessments. Services span Phase I through Phase IV trials across neuroscience (psychiatry, pain, neurology, addiction) and metabolic (obesity, diabetes, MASH) therapeutic areas, supported by a Scientific Leadership Team of 47 MDs and 12 PhDs/PsyDs.

Differentiator

Problem solved

Functional benefit

Brands

  • Summit Analytical: A wholly-owned division of Lotus Clinical Research providing biostatistical support across the full development lifecycle from early-phase trials to post-marketing and real-world evidence studies.

Products and services

  • Project Management Clinical trial project management services providing operational leadership, timeline management, risk mitigation, vendor coordination, and team communication. Project managers have average 10+ years industry tenure and act as extensions of sponsor teams.
  • Clinical Monitoring
  • Medical Monitoring
  • EDC & Data Management
  • Biostatistics & Summit Analytical
  • PK/PD Modeling & Simulation
  • Quality Operations
  • Global Rater Training & Certification
  • Placebo Response Mitigation (PRM)
  • Unified Site Methodology (USM) Program
  • Eligibility Review
  • Medical Writing
  • Clinical Development & Scientific Consultation
  • NeuroKit CNS Testing Platform Portable CNS testing platform adapted from CHDR's NeuroCart system, providing high-quality standardized CNS assessments including adaptive tracking, body sway, N-back test, VAS scales, saccadic eye movement, and smooth pursuit eye movement for Phase I-IIa trials. Available exclusively in the US through Lotus and ERG.
  • Phase I Clinical Pharmacology Units
  • Renal & Hepatic Studies
  • Biomarkers
  • Cardiac Safety
  • ERG Site Network

Companies that use Lotus Clinical Research

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Lotus Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature5 records

Lotus Clinical Research partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Centre for Human Drug Research (CHDR)coreTechnology or Integration · 13 October 2025Exclusive US partnership to bring NeuroKit CNS testing platform to the US market. NeuroKit is adapted from CHDR's NeuroCart system and is available exclusively in the US through Lotus and ERG. Clinical Pharmacology of Miami (CPMI) is the first US site to deploy the platform.
  • Veeva SystemscoreTechnology or Integration · 30 May 2023Expanded partnership using Veeva Vault Clinical Suite including Vault EDC, Vault CTMS, and Vault eTMF. The partnership enables substantial decrease in clinical trial startup time and improved operational efficiency across Lotus studies.
  • Evolution Research Group (ERG)coreStrategic or Co-development PartnerCommon ownership partnership providing integrated CRO and site network services. ERG operates 20 wholly-owned US-based research sites with 400+ beds, nine surgical centers, and Phase I units. Lotus-Sponsor studies are prioritized within the ERG network. The collaboration enables rapid study startup and prioritized enrollment for Lotus clients.
  • FNIH Biomarkers ConsortiumminorStrategic or Co-development PartnerERG holds membership in the FNIH Biomarkers Consortium with representation on the Metabolic Diseases Steering Committee. Subject matter experts contribute to supporting crucial development programs in metabolic diseases.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Lotus Clinical Research competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Largest global full-service CRO and clinical technology vendor with deep CNS and metabolic capabilities. Lotus competes for the same enterprise pharma accounts on bundled full-service offerings, though IQVIA's breadth dwarfs Lotus' specialty focus.
  • Fortrea (formerly LabCorp Drug Development): Top global full-service CRO spun out from LabCorp in 2023 with end-to-end Phase I-IV capabilities including CNS and metabolic therapeutic areas. Competes directly for mid- to large-pharma full-service outsourcing mandates.
  • Parexel International: Top-5 global CRO with broad CNS and metabolic therapeutic expertise acquired through legacy and recent clinical operations build-out. Competes for the same large-pharma outsourced trial mandates.
  • ICON plc: Largest pure-play global CRO (post-PRA merger) with full therapeutic-area coverage including CNS and metabolic. Competes with Lotus for large-pharma full-service Phase II-IV trials and biotech sponsor mandates.
  • Syneos Health: Global biopharmaceutical services organization spanning clinical development and commercial—offers comparable full-service CNS/metabolic CRO capabilities at larger scale. Competes on enterprise pharma outsourcing relationships and global trial footprint.

Direct peers

  • Worldwide Clinical Trials: Mid-sized specialty CRO with deep CNS, pain, and cardiometabolic expertise. Closest direct competitor to Lotus—competes for the same pharma/biotech sponsors running CNS and metabolic trials with comparable therapeutic-area focus and similar size/scale.
  • Premier Research: Specialty CRO emphasizing CNS, oncology, and rare disease trials with similar full-service model (project management through biostatistics). Lotus competes head-to-head on CNS and metabolic RFPs; now owned by KCR/Croone.
  • Clario: Major clinical trial technology and eCOA/ePRO vendor serving CNS and metabolic trials. Comparable function to Lotus' Veeva-integrated EDC/CTMS/eTMF stack and NeuroKit platform—competes on clinical trial informatics and endpoint data quality.
  • Altasciences: Early-phase CRO with dedicated Phase I clinical pharmacology units and integrated preclinical-to-clinical services. Direct overlap with Lotus' Clinical Pharmacology of Miami and Ohio Clinical Trials Phase I units serving healthy volunteer and special population studies.

Emerging players

  • Analgesic Solutions: Niche pain-CRO consultancy specializing in analgesic trial design, endpoint selection, and pain measurement—overlapping with Lotus' analgesic/pain trial focus (~600+ pain studies) and competing for the same sponsor pain franchise programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Lotus Clinical Research social profiles

Digital presence

Lotus Clinical Research compliance and trust

Trust signal

Compliance3 records

Lotus Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lotus Clinical Research leadership team

Management profile

Number of profiles

Profiles17 records

Lotus Clinical Research subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Lotus Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lotus Clinical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lotus Clinical Research

What does Lotus Clinical Research do?

Lotus Clinical Research is a full-service global Contract Research Organization (CRO) that runs neuroscience and metabolic clinical trials from first-in-human through late-phase development. The firm delivers project management, clinical monitoring, medical monitoring, EDC and data management, biostatistics, PK/PD modeling, and quality operations, complemented by proprietary scientific solutions such as Placebo Response Mitigation, Global Rater Training, and Unified Site Methodology. Through common ownership with Evolution Research Group (ERG), Lotus has priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units.

Is Lotus Clinical Research a public or private company?

Lotus Clinical Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lotus Clinical Research founded?

Lotus Clinical Research was founded in 2014. It employs 51 to 100 people.

Where is Lotus Clinical Research based?

Lotus Clinical Research is headquartered in New Providence, United States, in the North America region.

How does Lotus Clinical Research make money?

One revenue line is on record: full-Service CRO Services.

Who are Lotus Clinical Research's main competitors?

Broad incumbents on record are IQVIA, Fortrea (formerly LabCorp Drug Development), Parexel International, ICON plc and Syneos Health. Direct peers are Worldwide Clinical Trials, Premier Research, Clario and Altasciences. Analgesic Solutions is listed as an emerging player.

Does Lotus Clinical Research have an API?

No public API is recorded for Lotus Clinical Research.

What industry is Lotus Clinical Research in?

Lotus Clinical Research's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Globe and MailBunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, MallinckrodtDelveInsight forecasts the bunion market to grow significantly from 2020 to 2034, with the US leading at about $3 billion in 2023. Conservative treatment held a 40% revenue share, while bunionectomy dominated with 60%. The report also covers epidemiology and pipeline developments.PR NewswireETQ Adds Lotus Clinical Research to Roster of Life Sciences Firms Finding Success with ETQ Reliance Quality Management SystemLotus Clinical Research joined ETQ's roster of life sciences firms using ETQ Reliance for quality management. The CRO digitized manual functions, centralized quality data, and automated document control and CAPA plans. Lotus President Bill Martin said the system made the organization audit-ready.ContractpharmaLotus Clinical Research, Trialogics Partner for Clinical Trial Software ServicesLotus Clinical Research and Trialogics entered a strategic partnership to expand Lotus' use of Trialogics' clinical trial software. The collaboration aims to enhance data collection, streamline trial processes, and improve data quality, with Trialogics offering cloud-based and mobile data collection. The partnership will enable additional integrated solutions for sponsors.PR NewswireLotus Clinical Research Announces Strategic Partnership with Trialogics For Clinical Trial Software ServicesLotus Clinical Research has entered into a strategic partnership with Trialogics to expand its use of clinical trial software services. The collaboration aims to enhance data collection methods, streamline trial processes, and improve data quality through integrated solutions like ePRO and IRT. This move allows Lotus to offer more customized and efficient technological support for its clinical development clients.PR NewswireLotus Clinical Research étend son partenariat avec Veeva pour accélérer les essais cliniquesLotus Clinical Research, a growing CRO, has expanded its multi-year partnership with Veeva Systems to broaden its adoption of Veeva Vault Clinical Suite. The integration of Vault CDMS, Vault eTMF, and Vault CTMS has significantly reduced Lotus's clinical trial startup times while maintaining quality standards. This partnership has enabled Lotus to scale its operations and expand from its original focus on acute pain and CNS research to supporting all facets of clinical research across Phase 1-4 trials.PR NewswireLotus Clinical Research erweitert seine Partnerschaft mit Veeva zur Beschleunigung klinischer StudienVeeva Systems announced an expansion of its partnership with Lotus Clinical Research to include the Veeva Vault Clinical Suite, aiming to accelerate clinical trial timelines and improve operational efficiency. This strategic move allows Lotus to scale its studies and enhance coordination with sponsors and clinical sites through integrated cloud applications.PR NewswireLotus Clinical Research amplía la asociación con Veeva para acelerar los ensayos clínicosVeeva Systems announced that Lotus Clinical Research expanded its partnership and adoption of Veeva Vault Clinical Suite, including Vault CDMS, Vault eTMF, and Vault CTMS. Lotus, a fast-growing CRO, has significantly reduced study startup time by leveraging the unified clinical platform to manage clinical data, trial master file, and clinical trial management operations. The over-five-year partnership enables Lotus to scale its trial execution capacity while maintaining quality standards, supporting its transition from a focus on acute pain and CNS research to broader therapeutic areas.PR NewswireLotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical TrialsLotus Clinical Research expanded its partnership with Veeva Systems, broadening adoption of Veeva Vault Clinical Suite. The move reduces study startup time and supports higher trial volume. Lotus, a CRO, now uses integrated applications for faster EDC builds and streamlined monitoring.PR NewswireLotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical TrialsLotus Clinical Research expanded its partnership with Veeva Systems, broadening adoption of Veeva Vault Clinical Suite. The move reduces study startup time and supports higher trial volume. Lotus, a CRO, now uses the suite for in-house study design and integrated clinical applications.PR NewswireNeil Singla, MD, CEO at Lotus Clinical Research, Speaks on Opioid Sparing OutcomesNeil Singla, Chief Scientific Officer at Lotus Clinical Research, spoke at Arrowhead's Pain & Migraine Therapeutics Summit in Washington, D.C. on opioid sparing outcomes and FDA advisory committee updates, discussing how non-opioid drugs can reduce opioid consumption and the statistical challenges in demonstrating opioid sparing. Dr. Singla outlined pathways to success including appropriate Phase 2 work and clear regulatory communication strategies for achieving analgesic claims. Lotus Clinical Research, a dedicated analgesic CRO based in Pasadena, California, is actively conducting clinical trials to develop opioid alternatives for pain relief and management.